# Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

> **NCT04530630** · PHASE4 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 20 (actual)

## Conditions studied

- HIV Infections
- Renal Transplant Rejection

## Interventions

- **DRUG:** BIC/F/TAF 50Mg-200Mg-25Mg Tablet

## Key facts

- **NCT ID:** NCT04530630
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-09
- **Primary completion:** 2024-08-28
- **Final completion:** 2024-08-28
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-08-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530630, "Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04530630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*